Lipid Liquid Crystal Nanoparticles: Promising Photosensitizer Carriers for the Treatment of Infected Cutaneous Wounds

Cutaneous chronic wounds impose a silent pandemic that affects the lives of millions worldwide. The delayed healing process is usually complicated by opportunistic bacteria that infect wounds. <i>Staphylococcus aureus</i> is one of the most prevalent bacteria in infected cutaneous wounds...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhammed Awad (Author), Zlatko Kopecki (Author), Timothy J. Barnes (Author), Anthony Wignall (Author), Paul Joyce (Author), Nicky Thomas (Author), Clive A. Prestidge (Author)
Format: Book
Published: MDPI AG, 2023-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous chronic wounds impose a silent pandemic that affects the lives of millions worldwide. The delayed healing process is usually complicated by opportunistic bacteria that infect wounds. <i>Staphylococcus aureus</i> is one of the most prevalent bacteria in infected cutaneous wounds, with the ability to form antibiotic-resistant biofilms. Recently, we have demonstrated the potential of gallium protoporphyrin lipid liquid crystalline nanoparticles (GaPP-LCNP) as a photosensitizer against <i>S. aureus</i> biofilms in vitro. Herein, we investigate the potential of GaPP-LCNP using a pre-clinical model of infected cutaneous wounds. GaPP-LCNP showed superior antibacterial activity compared to unformulated GaPP, reducing biofilm bacterial viability by 5.5 log<sub>10</sub> compared to 2.5 log<sub>10</sub> in an ex vivo model, and reducing bacterial viability by 1 log<sub>10</sub> in vivo, while unformulated GaPP failed to reduce bacterial burden. Furthermore, GaPP-LCNP significantly promoted wound healing through reduction in the bacterial burden and improved early collagen deposition. These findings pave the way for future pre-clinical investigation and treatment optimizations to translate GaPP-LCNP towards clinical application.
Item Description:10.3390/pharmaceutics15020305
1999-4923